India to have more than sufficient stock of Liposomal Amphotericin B drug for the treatment of Mucormycosis: Mansukh Mandaviya
Follow The Hawk on Google News+ FollowAdvertisement
Total 7,28,045 vials of Liposomal Amphotericin B to all the states and Central institutions till 17th June, 2021
New Delhi (The Hawk): "On 16th June,2021, active cases of Mucormycosis were 27,142. Even in the future, if cases of Black fungus increases , India is prepared to have more than sufficient availability of Amphotericin B drug and other drugs which are required to treat patients of Mucormycosis. India has increased domestic production remarkably by more than fivefold. Domestic production of Liposomal Amphotericin B was just 62,000 vials in April,2021 and now it is expected to cross 3.75 lakh vials in June,2021. While increasing domestic production, India also placed order to import 9,05,000 Liposomal Amphotericin Bvials through M/s Mylan. India is leaving no stone unturned to boost the availability of Amphotericin B drugs in the country'', said Shri Mansukh Mandaviya, Minister of State for Chemicals & Fertilisers.
Advertisement
Department of Pharmaceuticals, Ministry of Chemicals & Fertilisers has allocated a total 7,28,045 vials ofLiposomal Amphotericin B to all the states and Central institutions till 17th June, 2021. Amphotericin B drug is used for the treatment of Mucormycosis, commonly known as Black Fungus.
Also readFSSAI to initiate action against Bisleri over unsafe water sampleGet The Hawk first on Google
Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.
Advertisement








